<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">34509883</PMID>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1525-5069</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>124</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
              <Day>09</Day>
            </PubDate>
          </JournalIssue>
          <Title>Epilepsy &amp; behavior : E&amp;B</Title>
          <ISOAbbreviation>Epilepsy Behav</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Safety and efficacy of rufinamide in children and adults with Lennox-Gastaut syndrome: A post hoc analysis from Study 022.</ArticleTitle>
        <Pagination>
          <StartPage>108275</StartPage>
          <MedlinePgn>108275</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.yebeh.2021.108275</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1525-5050(21)00536-9</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Lennox-Gastaut syndrome (LGS) is a developmental and epileptic encephalopathy with the first symptoms usually appearing during early childhood. Due to the highly variable underlying etiologies, LGS cannot be considered as one disease but as an electro-clinical entity, often challenging to diagnose early and treat accordingly. The anti-seizure medication, rufinamide, is indicated for the adjunctive treatment of patients with LGS aged ≥1 year. This post hoc analysis assessed the safety and efficacy of adjunctive rufinamide for total and tonic-atonic seizures during Study 022 in children (aged &lt;16 years) and adults (aged ≥16 years).</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Randomized, placebo-controlled, phase III Study 022 included patients with a diagnosis of LGS and a history of multiple seizure types (including tonic-atonic or astatic seizures and atypical absence seizures; ≥90 seizures in the month prior to baseline). Assessments included monitoring of treatment-emergent adverse events (TEAEs), percent change in tonic-atonic seizure frequency/28 days during the double-blind phase relative to study baseline (a primary endpoint), and percentage of patients with ≥25%, ≥50%, or ≥75% reduction in seizure frequency relative to baseline.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 138 enrolled patients, 74 received rufinamide (&lt;16 years, n = 49 [66%]) and 64 received placebo (&lt;16 years, n = 43 [67%]). Incidence of TEAEs was generally similar between age groups. The frequency (per 28 days) of tonic-atonic seizures was reduced with rufinamide (vs. placebo) in both younger and older patients: age &lt;16 years (-41% vs. -6%), age ≥16 years (-55% vs. +16%) (p &lt; 0.025; both age groups). In patients aged &lt;16 years receiving rufinamide, 38% and 17% achieved ≥50% and ≥75% reductions in tonic-atonic seizure frequency vs. 18% and 3% with placebo, respectively. Corresponding responder rates for patients aged ≥16 years were 52% and 32% (rufinamide) vs. 15% and 5% (placebo), respectively.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this post hoc analysis, adjunctive rufinamide was well tolerated and improved seizure control in patients with LGS, irrespective of age.</AbstractText>
          <CopyrightInformation>Copyright © 2021. Published by Elsevier Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Arzimanoglou</LastName>
            <ForeName>Alexis</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Paediatric Clinical Epileptology, Sleep Disorders and Functional Neurology, Member of the ERN EpiCARE, University Hospitals of Lyon (HCL), Lyon 60700, France; Epilepsy Research Coordinator, Children's Hospital San Juan de Dios, Member of the ERN EpiCARE, Barcelona 08950, Spain. Electronic address: aarzimanoglou@orange.fr.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pringsheim</LastName>
            <ForeName>Milka</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Clinic for Neuropediatrics and Neurological Rehabilitation, Epilepsy Center for Children and Adolescents, Krankenhausstr, Vogtareuth 20 83569, Germany; Research Institute for Rehabilitation, Transition and Palliation, PMU Salzburg, 5020 Salzburg, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kluger</LastName>
            <ForeName>Gerhard Josef</ForeName>
            <Initials>GJ</Initials>
            <AffiliationInfo>
              <Affiliation>Clinic for Neuropediatrics and Neurological Rehabilitation, Epilepsy Center for Children and Adolescents, Krankenhausstr, Vogtareuth 20 83569, Germany; Research Institute for Rehabilitation, Transition and Palliation, PMU Salzburg, 5020 Salzburg, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Genton</LastName>
            <ForeName>Pierre</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Centre Hospitalier, Avenue des Tamaris, 13100 Aix-en-Provence, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Perdomo</LastName>
            <ForeName>Carlos</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Eisai Inc., 100 Tice Boulevard, Woodcliff Lake, NJ 07677, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Malhotra</LastName>
            <ForeName>Manoj</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Eisai Inc., 100 Tice Boulevard, Woodcliff Lake, NJ 07677, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Epilepsy Behav</MedlineTA>
        <NlmUniqueID>100892858</NlmUniqueID>
        <ISSNLinking>1525-5050</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Adults</Keyword>
        <Keyword MajorTopicYN="N">Children</Keyword>
        <Keyword MajorTopicYN="N">Lennox-Gastaut syndrome</Keyword>
        <Keyword MajorTopicYN="N">Rufinamide</Keyword>
        <Keyword MajorTopicYN="N">Safety</Keyword>
        <Keyword MajorTopicYN="N">Tonic-atonic seizure</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>12</Day>
          <Hour>20</Hour>
          <Minute>55</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34509883</ArticleId>
        <ArticleId IdType="doi">10.1016/j.yebeh.2021.108275</ArticleId>
        <ArticleId IdType="pii">S1525-5050(21)00536-9</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
